

Supplement Table 2. Characteristics of study patients according to types of ARBs

	Overall (N=2,802)	Fimasartan (N=124)	Candesartan (N=845)	Valsartan (N=743)	Losartan (N=597)	Telmisartan (N=214)	Olmesartan (N=168)	Irbesartan (N=111)	p-value
Age, year, mean (SD)	65.2 (13.4)	64.1 (12.7)	65.1 (13.7)	64.9 (13.0)	64.9 (13.4)	68.2 (13.3)	65.3 (13.0)	65.5 (13.9)	0.06
Sex, male^{***}	1,924 (68.7)	79 (63.7)	606 (71.7)	531 (71.5)	410 (68.7)	126 (58.9)	107 (63.7)	65 (58.6)	<.001
Previous revascularization*	158 (5.6)	4 (3.2)	38 (4.5)	36 (4.8)	42 (7.0)	15 (7.0)	10 (6.0)	13 (11.7)	0.02
Previous ACEI/ARB^{***}	1,196 (42.7)	55 (44.4)	330 (39.1)	292 (39.3)	256 (42.9)	107 (50.0)	91 (54.2)	65 (58.6)	<.001
Charlson index, mean (SD)	0.8 (1.1)	0.8 (1.1)	0.8 (1.1)	0.7 (1.1)	0.8 (1.2)	0.9 (1.1)	0.9 (1.2)	1.1 (1.3)	0.05
Comorbidity									
Diabetes mellitus	626 (22.3)	30 (24.2)	191 (22.6)	150 (20.2)	125 (20.9)	51 (23.8)	44 (26.2)	35 (31.5)	0.12
Hypertension*	1,159 (41.4)	53 (42.7)	329 (38.9)	286 (38.5)	254 (42.5)	104 (48.6)	86 (51.2)	47 (42.3)	0.01
Hyperlipidemia	125 (4.5)	4 (3.2)	35 (4.1)	28 (3.8)	28 (4.7)	12 (5.6)	11 (6.5)	7 (6.3)	0.57
Atrial fibrillation of flutter*	44 (1.6)	1 (0.8)	11 (1.3)	12 (1.6)	6 (1.0)	6 (2.8)	2 (1.2)	6 (5.4)	0.02
COPD	229 (8.2)	8 (6.5)	61 (7.2)	63 (8.5)	53 (8.9)	21 (9.8)	14 (8.3)	9 (8.1)	0.84
Peripheral artery disease	54 (1.9)	3 (2.4)	17 (2.0)	12 (1.6)	10 (1.7)	6 (2.8)	5 (3.0)	1 (0.9)	0.78
Tertiary hospital^{***}	794 (28.3)	17 (13.7)	331 (39.2)	174 (23.4)	151 (25.3)	59 (27.6)	36 (21.4)	26 (23.4)	<.001
Medications at discharge									
Calcium channel blocker ^{***}	884 (31.5)	36 (29.0)	244 (28.9)	274 (36.9)	152 (25.5)	74 (34.6)	63 (37.5)	41 (36.9)	<.001
Statin ^{***}	2,605 (93.0)	117 (94.4)	791 (93.6)	662 (89.1)	570 (95.5)	209 (97.7)	157 (93.5)	99 (89.2)	<.001
Aspirin	2,761 (98.5)	124 (100.0)	834 (98.7)	735 (98.9)	585 (98.0)	210 (98.1)	165 (98.2)	108 (97.3)	0.48
Clopidogrel ^{***}	2,187 (78.1)	73 (58.9)	661 (78.2)	578 (77.8)	501 (83.9)	152 (71.0)	132 (78.6)	90 (81.1)	<.001

Ticagrelor or prasugrel***	794 (28.3)	50 (40.3)	267 (31.6)	215 (28.9)	129 (21.6)	62 (29.0)	51 (30.4)	20 (18.0)	<.001
Anticoagulant	92 (3.3)	3 (2.4)	33 (3.9)	19 (2.6)	21 (3.5)	7 (3.3)	7 (4.2)	2 (1.8)	0.7
Beta-blocker**	2,540 (90.6)	111 (89.5)	740 (87.6)	690 (92.9)	553 (92.6)	197 (92.1)	150 (89.3)	99 (89.2)	0.008
Spironolactone***	837 (29.9)	25 (20.2)	296 (35.0)	229 (30.8)	149 (25.0)	61 (28.5)	43 (25.6)	34 (30.6)	<.001

Values were presented n (%), mean (SD) or median (IQR).

*p< 0.05, **p< 0.01, ***p< 0.001

Abbreviations: ACEI, Angiotensin-converting enzyme inhibitor; ARB, Angiotensin receptor II blocker; COPD, chronic obstructive pulmonary disease; IQR, interquartile range; SD, standard deviation.